Vanguard International High Dividend Yield ETF vs DENTSPLY SIRONA Inc — how do they compare? Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 13.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard International High Dividend Yield ETF for 50 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| VYMI | XRAY | |
|---|---|---|
Market Cap | $22.80B | $1.73B |
Volume | 748,441 | 6,198,582 |
Sector | Broad Market / Factor | Health |
52-Week High | $107.13 | $14.68 |
52-Week Low | $82.92 | $8.52 |
Typical Hold Time | 50 Days | 72 Days |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.66, up 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on international high dividend yield stocks, with recent institutional buying activity from Envestnet and Corient Private Wealth. Recent news highlights strong performance with a 29% one-year return and 14.13% five-year average annual return, supported by financials, energy, and healthcare sector exposure.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's attractive dividend yield. Key risks include global economic volatility and currency fluctuations, but institutional accumulation and sector alignment with rising rates support the investment thesis for income-focused investors seeking international diversification.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →